{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:44:00Z","timestamp":1791218640205,"version":"4.1.0"},"reference-count":109,"publisher":"Wiley","issue":"S7","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":2526,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2008,10,1]]},"DOI":"10.1002\/cncr.23645","type":"journal-article","created":{"date-parts":[[2010,3,2]],"date-time":"2010-03-02T14:16:26Z","timestamp":1267539386000},"page":"1768-1778","source":"Crossref","is-referenced-by-count":38,"special_numbering":"supplement 7","title":["The von Hippel-Lindau gene"],"prefix":"10.1002","volume":"113","author":[{"given":"Peter E.","family":"Clark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Cookson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","reference":[{"key":"10.1002\/cncr.23645-BIB1","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(03)13643-4","article-title":"von Hippel-Lindau disease","volume":"361","author":"Lonser","year":"2003","journal-title":"Lancet."},{"key":"10.1002\/cncr.23645-BIB2","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/ncpuro0179","article-title":"Management of von Hippel-Lindau-associated kidney cancer","volume":"2","author":"Grubb","year":"2005","journal-title":"Nat Clin Pract Urol."},{"key":"10.1002\/cncr.23645-BIB3","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1136\/jmg.28.7.443","article-title":"Von Hippel-Lindau disease: a genetic study","volume":"28","author":"Maher","year":"1991","journal-title":"J Med Genet."},{"key":"10.1002\/cncr.23645-BIB4","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/0140-6736(91)91705-Y","article-title":"Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus","volume":"337","author":"Neumann","year":"1991","journal-title":"Lancet."},{"key":"10.1002\/cncr.23645-BIB5","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1093\/qjmed\/77.2.1151","article-title":"Clinical features and natural history of von Hippel-Lindau disease","volume":"77","author":"Maher","year":"1990","journal-title":"Q J Med."},{"key":"10.1002\/cncr.23645-BIB6","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1126\/science.8493574","article-title":"Identification of the von Hippel-Lindau disease tumor suppressor gene","volume":"260","author":"Latif","year":"1993","journal-title":"Science."},{"key":"10.1002\/cncr.23645-BIB7","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/ng0594-85","article-title":"Mutations of the VHL tumour suppressor gene in renal carcinoma","volume":"7","author":"Gnarra","year":"1994","journal-title":"Nat Genet."},{"key":"10.1002\/cncr.23645-BIB8","first-page":"1092","article-title":"Germ-line mutations in the von Hippel-Lindau tumor-suppressor gene are similar to somatic von Hippel-Lindau aberrations in sporadic renal cell carcinoma","volume":"55","author":"Whaley","year":"1994","journal-title":"Am J Hum Genet."},{"key":"10.1002\/cncr.23645-BIB9","first-page":"2852","article-title":"Frequent somatic mutations and loss of heterozygosity of the von Hippel-Lindau tumor suppressor gene in primary human renal cell carcinomas","volume":"54","author":"Shuin","year":"1994","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB10","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/hmg\/3.12.2169","article-title":"Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma","volume":"3","author":"Foster","year":"1994","journal-title":"Hum Mol Genet."},{"key":"10.1002\/cncr.23645-BIB11","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1093\/hmg\/3.8.1303","article-title":"Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype","volume":"3","author":"Crossey","year":"1994","journal-title":"Hum Mol Genet."},{"key":"10.1002\/cncr.23645-BIB12","doi-asserted-by":"crossref","first-page":"10914","DOI":"10.1073\/pnas.90.23.10914","article-title":"Antioncogenes and human cancer","volume":"90","author":"Knudson","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB13","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1073\/pnas.68.4.820","article-title":"Mutation and cancer: statistical study of retinoblastoma","volume":"68","author":"Knudson","year":"1971","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB14","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1038\/343774a0","article-title":"Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping","volume":"343","author":"Gessler","year":"1990","journal-title":"Nature."},{"key":"10.1002\/cncr.23645-BIB15","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1126\/science.3983638","article-title":"Genetic origin of mutations predisposing to retinoblastoma","volume":"228","author":"Cavenee","year":"1985","journal-title":"Science."},{"key":"10.1002\/cncr.23645-BIB16","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1126\/science.2885916","article-title":"Structural evidence for the authenticity of the human retinoblastoma gene","volume":"236","author":"Fung","year":"1987","journal-title":"Science."},{"key":"10.1002\/cncr.23645-BIB17","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/0092-8674(90)90024-9","article-title":"The neurofibromatosis type 1 gene encodes a protein related to GAP","volume":"62","author":"Xu","year":"1990","journal-title":"Cell."},{"key":"10.1002\/cncr.23645-BIB18","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/363495a0","article-title":"Cancer. A gene for neurofibromatosis 2","volume":"363","author":"Kinzler","year":"1993","journal-title":"Nature."},{"key":"10.1002\/cncr.23645-BIB19","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1056\/NEJM197909133011107","article-title":"Hereditary renal-cell carcinoma associated with a chromosomal translocation","volume":"301","author":"Cohen","year":"1979","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23645-BIB20","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/ijc.2910430313","article-title":"Tissue-specific expression of a constitutional 3;6 translocation: development of multiple bilateral renal-cell carcinomas","volume":"43","author":"Kovacs","year":"1989","journal-title":"Int J Cancer."},{"key":"10.1002\/cncr.23645-BIB21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1126\/science.7112106","article-title":"Familial renal cell carcinoma with a 3;11 chromosome translocation limited to tumor cells","volume":"217","author":"Pathak","year":"1982","journal-title":"Science."},{"issue":"4 pt 2","key":"10.1002\/cncr.23645-BIB22","first-page":"2139","article-title":"Cytogenetic studies of tumor tissue from patients with nonfamilial renal cell carcinoma","volume":"46","author":"Yoshida","year":"1986","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB23","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/0165-4608(88)90092-1","article-title":"Cytogenetics of 12 cases of renal adenocarcinoma","volume":"30","author":"de Jong","year":"1988","journal-title":"Cancer Genet Cytogenet."},{"key":"10.1002\/cncr.23645-BIB24","first-page":"1544","article-title":"Histopathological, cytogenetic, and molecular characterization of renal cortical tumors","volume":"51","author":"Presti","year":"1991","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB25","first-page":"651","article-title":"Clonal chromosome abnormalities in tumor cells from patients with sporadic renal cell carcinomas","volume":"49","author":"Kovacs","year":"1989","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB26","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0165-4608(87)90072-0","article-title":"Deletion 3p: the only chromosome loss in a primary renal cell carcinoma","volume":"26","author":"Szucs","year":"1987","journal-title":"Cancer Genet Cytogenet."},{"key":"10.1002\/cncr.23645-BIB27","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/327721a0","article-title":"Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma","volume":"327","author":"Zbar","year":"1987","journal-title":"Nature."},{"key":"10.1002\/cncr.23645-BIB28","first-page":"1071","article-title":"Molecular analysis of genetic changes in the origin and development of renal cell carcinoma","volume":"51","author":"Anglard","year":"1991","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/332268a0","article-title":"Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma","volume":"332","author":"Seizinger","year":"1988","journal-title":"Nature."},{"key":"10.1002\/cncr.23645-BIB30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/BF00201543","article-title":"Isolation and regional localization of a large collection (2,000) of single-copy DNA fragments on human chromosome 3 for mapping and cloning tumor suppressor genes","volume":"86","author":"Lerman","year":"1991","journal-title":"Hum Genet."},{"key":"10.1002\/cncr.23645-BIB31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/0888-7543(90)90249-T","article-title":"Localization of the von Hippel-Lindau disease gene to a small region of chromosome 3","volume":"8","author":"Hosoe","year":"1990","journal-title":"Genomics."},{"key":"10.1002\/cncr.23645-BIB32","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1007\/BF00420947","article-title":"von Hippel-Lindau disease: identification of deletion mutations by pulsed-field gel electrophoresis","volume":"92","author":"Yao","year":"1993","journal-title":"Hum Genet."},{"key":"10.1002\/cncr.23645-BIB33","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/jama.1995.03520310062031","article-title":"Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer","volume":"273","author":"Linehan","year":"1995","journal-title":"JAMA."},{"key":"10.1002\/cncr.23645-BIB34","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1111\/j.1749-6632.1991.tb37775.x","article-title":"Toward the isolation of the primary genetic defect in von Hippel-Lindau disease","volume":"615","author":"Seizinger","year":"1991","journal-title":"Ann N Y Acad Sci."},{"key":"10.1002\/cncr.23645-BIB35","first-page":"201","article-title":"Molecular cloning of the von Hippel-Lindau tumor suppressor gene and its role in renal carcinoma","volume":"1242","author":"Gnarra","year":"1996","journal-title":"Biochim Biophys Acta."},{"key":"10.1002\/cncr.23645-BIB36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1046\/j.1365-2796.1998.00334.x","article-title":"Molecular genetic analysis of von Hippel-Lindau disease","volume":"243","author":"Richards","year":"1998","journal-title":"J Intern Med."},{"key":"10.1002\/cncr.23645-BIB37","doi-asserted-by":"crossref","first-page":"9700","DOI":"10.1073\/pnas.91.21.9700","article-title":"Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma","volume":"91","author":"Herman","year":"1994","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB38","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000472284","article-title":"DNA-based presymptomatic diagnosis for the von Hippel-Lindau disease by linkage analysis","volume":"3","author":"Olschwang","year":"1995","journal-title":"Eur J Hum Genet."},{"key":"10.1002\/cncr.23645-BIB39","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/humu.1380050109","article-title":"Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype","volume":"5","author":"Chen","year":"1995","journal-title":"Hum Mutat."},{"key":"10.1002\/cncr.23645-BIB40","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1136\/jmg.33.4.328","article-title":"Phenotypic expression in von Hippel-Lindau disease: correlations with germline VHL gene mutations","volume":"33","author":"Maher","year":"1996","journal-title":"J Med Genet."},{"key":"10.1002\/cncr.23645-BIB41","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/BF00223868","article-title":"Von Hippel-Lindau (VHL) disease with pheochromocytoma in the Black Forest region of Germany: evidence for a founder effect","volume":"95","author":"Brauch","year":"1995","journal-title":"Hum Genet."},{"key":"10.1002\/cncr.23645-BIB42","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jmg.33.8.716","article-title":"Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A","volume":"33","author":"Chen","year":"1996","journal-title":"J Med Genet."},{"key":"10.1002\/cncr.23645-BIB43","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1038\/nm0895-822","article-title":"Tumour suppression by the human von Hippel-Lindau gene product","volume":"1","author":"Iliopoulos","year":"1995","journal-title":"Nat Med."},{"key":"10.1002\/cncr.23645-BIB44","doi-asserted-by":"crossref","first-page":"10589","DOI":"10.1073\/pnas.93.20.10589","article-title":"Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene","volume":"93","author":"Gnarra","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB45","doi-asserted-by":"crossref","first-page":"8817","DOI":"10.1073\/pnas.95.15.8817","article-title":"A second major native von Hippel-Lindau gene product, initiated from an internal translation start site, functions as a tumor suppressor","volume":"95","author":"Schoenfeld","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB46","doi-asserted-by":"crossref","first-page":"10595","DOI":"10.1073\/pnas.93.20.10595","article-title":"Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein","volume":"93","author":"Iliopoulos","year":"1996","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB47","first-page":"2299","article-title":"Reversion of deregulated expression of vascular endothelial growth factor in human renal carcinoma cells by von Hippel-Lindau tumor suppressor protein","volume":"56","author":"Siemeister","year":"1996","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB48","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1158\/1078-0432.CCR-06-2721","article-title":"Chromosomes, hypoxia, angiogenesis, and trial design: a brief history of renal cancer drug development","volume":"13","author":"Stadler","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23645-BIB49","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1073\/pnas.90.9.4304","article-title":"General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia","volume":"90","author":"Wang","year":"1993","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB50","doi-asserted-by":"crossref","first-page":"F271","DOI":"10.1152\/ajprenal.00071.2006","article-title":"Hypoxia-inducible factors in the kidney","volume":"291","author":"Haase","year":"2006","journal-title":"Am J Physiol Renal Physiol."},{"issue":"2 pt 2","key":"10.1002\/cncr.23645-BIB51","doi-asserted-by":"crossref","first-page":"680s","DOI":"10.1158\/1078-0432.CCR-06-1865","article-title":"The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma","volume":"13","author":"Kaelin","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23645-BIB52","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.semcdb.2005.03.006","article-title":"The VHL tumor suppressor in development and disease: functional studies in mice by conditional gene targeting","volume":"16","author":"Haase","year":"2005","journal-title":"Semin Cell Dev Biol."},{"key":"10.1002\/cncr.23645-BIB53","first-page":"2957","article-title":"Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation","volume":"62","author":"Turner","year":"2002","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB54","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1126\/science.7660122","article-title":"Inhibition of transcription elongation by the VHL tumor suppressor protein","volume":"269","author":"Duan","year":"1995","journal-title":"Science."},{"key":"10.1002\/cncr.23645-BIB55","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.7660130","article-title":"Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C","volume":"269","author":"Kibel","year":"1995","journal-title":"Science."},{"key":"10.1002\/cncr.23645-BIB56","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1073\/pnas.94.6.2156","article-title":"The von Hippel-Lindau tumor-suppressor gene product forms a stable complex with human CUL-2, a member of the Cdc53 family of proteins","volume":"94","author":"Pause","year":"1997","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB57","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1126\/science.284.5414.657","article-title":"Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase","volume":"284","author":"Kamura","year":"1999","journal-title":"Science."},{"key":"10.1002\/cncr.23645-BIB58","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1126\/science.284.5413.455","article-title":"Structure of the VHL-ElonginC-ElonginB complex: implications for VHL tumor suppressor function","volume":"284","author":"Stebbins","year":"1999","journal-title":"Science."},{"key":"10.1002\/cncr.23645-BIB59","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S1097-2765(00)80233-6","article-title":"Formation of the VHL-elongin BC tumor suppressor complex is mediated by the chaperonin TRiC","volume":"4","author":"Feldman","year":"1999","journal-title":"Mol Cell."},{"key":"10.1002\/cncr.23645-BIB60","doi-asserted-by":"crossref","first-page":"12436","DOI":"10.1073\/pnas.96.22.12436","article-title":"Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex","volume":"96","author":"Iwai","year":"1999","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB61","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1101\/gad.13.14.1822","article-title":"The von Hippel-Lindau tumor suppressor protein is a component of an E3 ubiquitin-protein ligase activity","volume":"13","author":"Lisztwan","year":"1999","journal-title":"Genes Dev."},{"key":"10.1002\/cncr.23645-BIB62","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/20459","article-title":"The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis","volume":"399","author":"Maxwell","year":"1999","journal-title":"Nature."},{"key":"10.1002\/cncr.23645-BIB63","doi-asserted-by":"crossref","first-page":"22642","DOI":"10.1074\/jbc.272.36.22642","article-title":"Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes","volume":"272","author":"Salceda","year":"1997","journal-title":"J Biol Chem."},{"key":"10.1002\/cncr.23645-BIB64","doi-asserted-by":"crossref","first-page":"25733","DOI":"10.1074\/jbc.M002740200","article-title":"Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein","volume":"275","author":"Cockman","year":"2000","journal-title":"J Biol Chem."},{"key":"10.1002\/cncr.23645-BIB65","doi-asserted-by":"crossref","first-page":"4298","DOI":"10.1093\/emboj\/19.16.4298","article-title":"Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein","volume":"19","author":"Tanimoto","year":"2000","journal-title":"Embo J."},{"key":"10.1002\/cncr.23645-BIB66","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1038\/35017054","article-title":"Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein","volume":"2","author":"Ohh","year":"2000","journal-title":"Nat Cell Biol."},{"key":"10.1002\/cncr.23645-BIB67","doi-asserted-by":"crossref","first-page":"10430","DOI":"10.1073\/pnas.190332597","article-title":"Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex","volume":"97","author":"Kamura","year":"2000","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB68","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1038\/ki.1997.82","article-title":"Regulation of vascular endothelial growth factor by hypoxia and its modulation by the von Hippel-Lindau tumor suppressor gene","volume":"51","author":"Levy","year":"1997","journal-title":"Kidney Int."},{"key":"10.1002\/cncr.23645-BIB69","first-page":"5215","article-title":"Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas","volume":"61","author":"Wiesener","year":"2001","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB70","first-page":"226","article-title":"Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor","volume":"58","author":"Knebelmann","year":"1998","journal-title":"Cancer Res."},{"key":"10.1002\/cncr.23645-BIB71","doi-asserted-by":"crossref","first-page":"5435","DOI":"10.1038\/sj.onc.1203938","article-title":"Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function","volume":"19","author":"Krieg","year":"2000","journal-title":"Oncogene."},{"key":"10.1002\/cncr.23645-BIB72","doi-asserted-by":"crossref","first-page":"12596","DOI":"10.1073\/pnas.95.21.12596","article-title":"Down-regulation of transmembrane carbonic anhydrases in renal cell carcinoma cell lines by wild-type von Hippel-Lindau transgenes","volume":"95","author":"Ivanov","year":"1998","journal-title":"Proc Natl Acad Sci USA."},{"key":"10.1002\/cncr.23645-BIB73","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nrm1366","article-title":"Oxygen sensing by HIF hydroxylases","volume":"5","author":"Schofield","year":"2004","journal-title":"Nat Rev Mol Cell Biol."},{"key":"10.1002\/cncr.23645-BIB74","doi-asserted-by":"crossref","first-page":"10931","DOI":"10.1016\/S0021-9258(19)49853-0","article-title":"Angiogenesis","volume":"267","author":"Folkman","year":"1992","journal-title":"J Biol Chem."},{"key":"10.1002\/cncr.23645-BIB75","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/0090-4295(86)90412-7","article-title":"Detection of tumor angiogenesis factor in adenocarcinoma of kidney","volume":"27","author":"Bard","year":"1986","journal-title":"Urology."},{"key":"10.1002\/cncr.23645-BIB76","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1200\/JCO.2005.01.186","article-title":"Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma","volume":"23","author":"Rini","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23645-BIB77","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.febslet.2006.03.087","article-title":"Biology of vascular endothelial growth factors","volume":"580","author":"Roy","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1002\/cncr.23645-BIB78","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1200\/JCO.2005.06.081","article-title":"Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis","volume":"23","author":"Hicklin","year":"2005","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23645-BIB79","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1159\/000088478","article-title":"VEGF as a key mediator of angiogenesis in cancer","volume":"69","author":"Carmeliet","year":"2005","journal-title":"Oncology."},{"key":"10.1002\/cncr.23645-BIB80","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.currproblcancer.2005.11.001","article-title":"Targeting VEGF in cancer therapy","volume":"30","author":"Donovan","year":"2006","journal-title":"Curr Probl Cancer."},{"key":"10.1002\/cncr.23645-BIB81","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.urology.2006.09.028","article-title":"Targeted molecular therapy for renal cell carcinoma","volume":"69","author":"Lane","year":"2007","journal-title":"Urology."},{"key":"10.1002\/cncr.23645-BIB82","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s003450000191","article-title":"Systemic chemotherapy and chemoimmunotherapy for metastatic renal cell cancer","volume":"19","author":"Heinzer","year":"2001","journal-title":"World J Urol."},{"key":"10.1002\/cncr.23645-BIB83","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0022-5347(17)57082-2","article-title":"The natural history of metastatic renal cell carcinoma: a computer analysis","volume":"120","author":"Dekernion","year":"1978","journal-title":"J Urol."},{"key":"10.1002\/cncr.23645-BIB84","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S0022-5347(05)67889-5","article-title":"Systemic therapy for renal cell carcinoma","volume":"163","author":"Motzer","year":"2000","journal-title":"J Urol."},{"key":"10.1002\/cncr.23645-BIB85","first-page":"42","article-title":"Chemotherapy for advanced renal-cell carcinoma: 1983-1993","volume":"22","author":"Yagoda","year":"1995","journal-title":"Semin Oncol."},{"key":"10.1002\/cncr.23645-BIB86","first-page":"148","article-title":"Cytokine therapy for metastatic renal cell carcinoma","volume":"19","author":"Bukowski","year":"2001","journal-title":"Semin Urol Oncol."},{"key":"10.1002\/cncr.23645-BIB87","first-page":"72","article-title":"Biology of renal cell carcinoma: changing concepts in classification and staging","volume":"19","author":"Pantuck","year":"2001","journal-title":"Semin Urol Oncol."},{"key":"10.1002\/cncr.23645-BIB88","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1056\/NEJMoa021491","article-title":"A randomized trial of bevacizumab, an antivascular endothelial growth factor antibody, for metastatic renal cancer","volume":"349","author":"Yang","year":"2003","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23645-BIB89","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1158\/1078-0432.CCR-03-0605","article-title":"Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus antivascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma","volume":"10","author":"Rini","year":"2004","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23645-BIB90","doi-asserted-by":"crossref","first-page":"6240","DOI":"10.1158\/1078-0432.CCR-04-2466","article-title":"Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies","volume":"11","author":"Kuenen","year":"2005","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23645-BIB91","first-page":"1648","article-title":"Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma","volume":"9","author":"Kuenen","year":"2003","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23645-BIB92","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1080\/07357900600896315","article-title":"Targeted therapy for renal cell carcinoma: a new therapeutic paradigm","volume":"24","author":"Shaheen","year":"2006","journal-title":"Cancer Invest."},{"key":"10.1002\/cncr.23645-BIB93","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/annonc\/mdi002","article-title":"Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens","volume":"16","author":"Amato","year":"2005","journal-title":"Ann Oncol."},{"key":"10.1002\/cncr.23645-BIB94","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1038\/nrd2130","article-title":"Discovery and development of sorafenib: a multikinase inhibitor for treating cancer","volume":"5","author":"Wilhelm","year":"2006","journal-title":"Nat Rev Drug Discov."},{"key":"10.1002\/cncr.23645-BIB95","doi-asserted-by":"crossref","first-page":"4478","DOI":"10.1200\/JCO.2002.11.126","article-title":"Randomized discontinuation design: application to cytostatic antineoplastic agents","volume":"20","author":"Rosner","year":"2002","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23645-BIB96","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1200\/JCO.2005.03.6723","article-title":"Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma","volume":"24","author":"Ratain","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23645-BIB97","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23645-BIB98","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nbt1068","article-title":"A small molecule-kinase interaction map for clinical kinase inhibitors","volume":"23","author":"Fabian","year":"2005","journal-title":"Nat Biotechnol."},{"key":"10.1002\/cncr.23645-BIB99","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23645-BIB100","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","article-title":"Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer","volume":"24","author":"Faivre","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23645-BIB101","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med."},{"key":"10.1002\/cncr.23645-BIB102","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23645-BIB103","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1001\/jama.295.21.2516","article-title":"Sunitinib in patients with metastatic renal cell carcinoma","volume":"295","author":"Motzer","year":"2006","journal-title":"JAMA."},{"key":"10.1002\/cncr.23645-BIB104","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/0008-5472.CAN-3554-2","article-title":"Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells","volume":"64","author":"Boulay","year":"2004","journal-title":"Cancer Res."},{"issue":"2 pt 2","key":"10.1002\/cncr.23645-BIB105","doi-asserted-by":"crossref","first-page":"758s","DOI":"10.1158\/1078-0432.CCR-06-1986","article-title":"The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer","volume":"13","author":"Cho","year":"2007","journal-title":"Clin Cancer Res."},{"key":"10.1002\/cncr.23645-BIB106","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3816\/CGC.2006.n.026","article-title":"Current data with mammalian target of rapamycin inhibitors in advanced-stage renal cell carcinoma","volume":"5","author":"Reddy","year":"2006","journal-title":"Clin Genitourin Cancer."},{"key":"10.1002\/cncr.23645-BIB107","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1200\/JCO.2004.08.185","article-title":"Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma","volume":"22","author":"Atkins","year":"2004","journal-title":"J Clin Oncol."},{"key":"10.1002\/cncr.23645-BIB108","first-page":"384","article-title":"Update of a phase I study of intravenous CCI-779 given in combination with interferon-a to patients with advanced renal cell carcinoma","volume":"23","author":"Smith","year":"2004","journal-title":"Proc Am Soc Clin Oncol."},{"key":"10.1002\/cncr.23645-BIB109","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med."}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.23645","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/cncr.23645\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,24]],"date-time":"2021-10-24T03:45:04Z","timestamp":1635047104000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cncr.23645"}},"subtitle":["Turning discovery into therapy"],"short-title":[],"issued":{"date-parts":[[2008,10,1]]},"references-count":109,"journal-issue":{"issue":"S7","published-print":{"date-parts":[[2008,10,1]]}},"URL":"https:\/\/doi.org\/10.1002\/cncr.23645","relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,10,1]]}}}